Bicycle Therapeutics (NASDAQ:BCYC) Research Coverage Started at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I started coverage on shares of Bicycle Therapeutics (NASDAQ:BCYCGet Rating) in a research report released on Thursday, Benzinga reports. The firm issued a buy rating and a $55.00 price target on the stock.

Several other research firms also recently weighed in on BCYC. Piper Sandler increased their price target on shares of Bicycle Therapeutics from $37.00 to $48.00 in a research report on Thursday, November 10th. Cantor Fitzgerald restated an overweight rating on shares of Bicycle Therapeutics in a research report on Wednesday, September 21st. JMP Securities decreased their price objective on shares of Bicycle Therapeutics from $70.00 to $46.00 and set a market outperform rating on the stock in a research report on Wednesday, November 9th. Finally, Morgan Stanley decreased their price objective on shares of Bicycle Therapeutics from $60.00 to $45.00 and set an equal weight rating on the stock in a research report on Monday, September 12th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Bicycle Therapeutics has a consensus rating of Moderate Buy and an average target price of $52.64.

Bicycle Therapeutics Stock Up 1.3 %

BCYC opened at $31.19 on Thursday. The company has a current ratio of 9.18, a quick ratio of 9.18 and a debt-to-equity ratio of 0.10. Bicycle Therapeutics has a 1-year low of $12.08 and a 1-year high of $54.80. The company has a market capitalization of $926.00 million, a PE ratio of -9.12 and a beta of 0.78. The firm’s 50 day simple moving average is $28.72 and its two-hundred day simple moving average is $24.87.

Bicycle Therapeutics (NASDAQ:BCYCGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.02. Bicycle Therapeutics had a negative net margin of 669.65% and a negative return on equity of 31.56%. The business had revenue of $3.04 million for the quarter, compared to the consensus estimate of $4.93 million. As a group, equities analysts forecast that Bicycle Therapeutics will post -3.82 EPS for the current year.

Insider Activity at Bicycle Therapeutics

In related news, insider Nigel Crockett sold 1,801 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $29.06, for a total transaction of $52,337.06. Following the completion of the transaction, the insider now directly owns 30,699 shares of the company’s stock, valued at $892,112.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Bicycle Therapeutics news, insider Nigel Crockett sold 1,801 shares of Bicycle Therapeutics stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $29.06, for a total value of $52,337.06. Following the completion of the transaction, the insider now directly owns 30,699 shares of the company’s stock, valued at approximately $892,112.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin Lee sold 6,000 shares of Bicycle Therapeutics stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $29.06, for a total transaction of $174,360.00. Following the completion of the transaction, the chief executive officer now directly owns 326,585 shares of the company’s stock, valued at $9,490,560.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,616 shares of company stock valued at $279,441. Corporate insiders own 9.00% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in BCYC. Tower Research Capital LLC TRC grew its stake in shares of Bicycle Therapeutics by 109.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,263 shares of the company’s stock worth $53,000 after buying an additional 1,184 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter worth $60,000. Virtus ETF Advisers LLC grew its stake in shares of Bicycle Therapeutics by 166.0% in the 2nd quarter. Virtus ETF Advisers LLC now owns 7,946 shares of the company’s stock worth $133,000 after buying an additional 4,959 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth about $183,000. Finally, UBS Group AG lifted its holdings in shares of Bicycle Therapeutics by 45.9% in the 2nd quarter. UBS Group AG now owns 12,966 shares of the company’s stock worth $218,000 after acquiring an additional 4,082 shares during the last quarter. 77.88% of the stock is owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

(Get Rating)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Read More

Analyst Recommendations for Bicycle Therapeutics (NASDAQ:BCYC)

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.